2020
380-P: Hypoglycemia among Nursing Home Residents with Diabetes Detected by Continuous Glucose Monitoring (CGM)
LIPSKA K, DOYLE M, CENGIZ E, DROZDOWICZ B, GILL T, MURPHY T, INZUCCHI S. 380-P: Hypoglycemia among Nursing Home Residents with Diabetes Detected by Continuous Glucose Monitoring (CGM). Diabetes 2020, 69 DOI: 10.2337/db20-380-p.Peer-Reviewed Original ResearchContinuous glucose monitoringNursing home residentsHome residentsNursing homesConsecutive blood glucose levelsFlash continuous glucose monitoringPatients 65 yearsChronic kidney diseaseFrequency of hypoglycemiaLexicon PharmaceuticalsType 2 diabetesBlood glucose levelsWilcoxon rank sum testRank sum testMannKind CorporationAdvisory PanelConnecticut nursing homesADL disabilityMedian ageKidney diseaseNovo Nordisk A/SCGM periodGlucose levelsHypoglycemiaLong-term residents1128-P: Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME Trial
NEELAND I, ELIASSON B, KASAI T, MARX N, ZINMAN B, INZUCCHI S, WANNER C, ZWIENER I, WOJECK B, YAGGI H, JOHANSEN O. 1128-P: Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME Trial. Diabetes 2020, 69 DOI: 10.2337/db20-1128-p.Peer-Reviewed Original ResearchObstructive sleep apneaNew-onset obstructive sleep apneaCardiovascular diseaseDohme Corp.Novo Nordisk A/SMundipharma InternationalMerck SharpEli LillyEMPA-REG OUTCOMEIncident obstructive sleep apneaFavorable metabolic effectsSanofi-AventisSystolic blood pressureCoronary artery diseaseType 2 diabetesAdvisory PanelEMPA-REGOSA statusPhilips RespironicsSanofi GenzymeSevere obesityArtery diseaseBlood pressureWaist circumferenceSleep apnea131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome
INZUCCHI S, ZINMAN B, WANNER C, FITCHETT D, ANKER S, POCOCK S, KASPERS S, GEORGE J, JOHANSEN O, JAMAL W, HANTEL S, LUND S. 131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome. Diabetes 2020, 69 DOI: 10.2337/db20-131-lb.Peer-Reviewed Original ResearchAtherosclerotic cardiovascular diseaseEMPA-REG OUTCOMEEffect of empagliflozinTotal burdenEli LillyHeart failure riskType 2 diabetesNervous system disordersTotal eventsAdvisory PanelSt. Jude MedicalLowest NNTMundipharma InternationalSanofi GenzymeCause hospitalizationCause mortalityCardiovascular mortalityFrequent hospitalizationsDohme Corp.Novo Nordisk A/SCardiovascular diseaseCardiac dimensionsHospitalization categoriesSystem disordersEmpagliflozin132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects
INZUCCHI S, KRAUS B, WEIR M, BAKRIS G, MATTHEUS M, CHERNEY D, SATTAR N, HEERSPINK H, RITTER I, EYNATTEN M, ZINMAN B, WANNER C, KOITKA-WEBER A. 132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects. Diabetes 2020, 69 DOI: 10.2337/db20-132-lb.Peer-Reviewed Original ResearchBoehringer Ingelheim-LillyCV deathBoehringer Ingelheim PharmaceuticalsMundipharma InternationalBaseline characteristicsNovo Nordisk A/SJanssen PharmaceuticalsEli LillyRisk reductionEMPA-REG OUTCOMEKDIGO risk categoriesPredictive baseline factorsRenal hemodynamic effectsSerious adverse eventsAdvanced kidney diseaseAdvisory PanelGlomerular filtration rateJanssen Scientific AffairsMultivariate logistic regressionDeath risk reductionNovo NordiskDiuretic therapyEGFR declineSanofi GenzymeCV disease23-OR: EHR-Based Blood Glucose Alerts Improve Inpatient Glycemic Control at a Large Academic Medical Center
BAK L, FANDEL T, BOZZO J, DEWITT M, CHEN P, PANDO R, FERRO L, KAPLAN R, HENDRICKSON K, AMPORT S, SUSSMAN L, INZUCCHI S. 23-OR: EHR-Based Blood Glucose Alerts Improve Inpatient Glycemic Control at a Large Academic Medical Center. Diabetes 2020, 69 DOI: 10.2337/db20-23-or.Peer-Reviewed Original ResearchAcademic medical centerLarge academic medical centerMedical CenterBG controlEHR-based interventionsInsulin order setsNon-ICU wardsBlood glucose managementInpatient glycemic controlElectronic health recordsControl wardsGlycemic controlSignificant hyperglycemiaNovo Nordisk A/SGlucose managementScore 2Severe hyperIndividual wardsControl groupOrder setsWardsHealth recordsLexicon PharmaceuticalsBG managementHypoglycemia28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME
VERMA S, LEITER L, SHARMA A, ZINMAN B, MATTHEUS M, FITCHETT D, GEORGE J, OFSTAD A, WANNER C, INZUCCHI S. 28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME. Diabetes 2020, 69 DOI: 10.2337/db20-28-or.Peer-Reviewed Original ResearchCV deathEMPA-REG OUTCOMEAtherosclerotic cardiovascular diseaseHazard ratioNovo Nordisk A/SJanssen PharmaceuticalsBristol-Myers SquibbTreatment initiationEli LillyEMPA-REG OUTCOME trialCox proportional hazards modelAdvisory PanelBenefits of empagliflozinRisk of HHFRisk of hospitalizationNumber of patientsType 2 diabetesProportional hazards modelCumulative incidence curvesNovartis Pharmaceuticals CorporationPost Hoc AnalysisBayer AGBoehringer Ingelheim PharmaceuticalsEmpagliflozin 10Empagliflozin doses927-P: Effect of Oral Semaglutide with or without Background SGLT2i in Patients with T2D: Subgroup Analysis of PIONEER 4
PRATLEY R, BAUER R, INZUCCHI S, KHUNTI K, KREINER E, LAURSEN P, MEIER J. 927-P: Effect of Oral Semaglutide with or without Background SGLT2i in Patients with T2D: Subgroup Analysis of PIONEER 4. Diabetes 2020, 69 DOI: 10.2337/db20-927-p.Peer-Reviewed Original ResearchNovo Nordisk A/SDohme Corp.Oral semaglutideMerck SharpGLP-1RAsSanofi-AventisNovartis AGRoche PharmaSGLT2 inhibitorsSubgroup analysisEli LillyGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsDaily oral semaglutideTrial product estimandGastrointestinal adverse eventsLexicon PharmaceuticalsSubgroup of patientsJanssen Scientific AffairsType 2 diabetesBayer AGBoehringer Ingelheim PharmaceuticalsAdvisory PanelSubcutaneous liraglutideT2D duration271-OR: ADA Presidents’ Select Abstract: Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HF
INZUCCHI S, DOCHERTY K, KOBER L, KOSIBOROD M, MARTINEZ F, PONIKOWSKI P, SABATINE M, SOLOMON S, BELOHLAVEK J, BÖHM M, CHIANG C, DE BOER R, DIEZ M, DUKAT A, LJUNGMAN C, VERMA S, DEMETS D, BENGTSSON O, LANGKILDE A, SJÖSTRAND M, JHUND P, MCMURRAY J. 271-OR: ADA Presidents’ Select Abstract: Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HF. Diabetes 2020, 69 DOI: 10.2337/db20-271-or.Peer-Reviewed Original ResearchNovartis Pharmaceuticals CorporationBoehringer Ingelheim PharmaceuticalsBristol-Myers SquibbIncidence of diabetesNovo Nordisk A/SHeart failureJanssen PharmaceuticalsNovartis AGDAPA-HFEisai Inc.Incident T2DSpeakers bureauEli LillyGlaxoSmithKline plcCox proportional hazards modelDaiichi SankyoBenefit of dapagliflozinNew-onset T2DPrespecified exploratory analysisSGLT2 inhibitor dapagliflozinNew-onset diabetesAdvisory PanelEffect of dapagliflozinPfizer Inc.Janssen Scientific Affairs
2019
159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME
ZINMAN B, FITCHETT D, MATTHEUS M, WANNER C, GEORGE J, VEDIN O, INZUCCHI S, JOHANSEN O. 159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME. Diabetes 2019, 68 DOI: 10.2337/db19-159-lb.Peer-Reviewed Original ResearchEMPA-REG OUTCOMEAdverse eventsBoehringer Ingelheim PharmaceuticalsPlasma glucoseMyocardial infarctionCause deathCV outcomesJanssen PharmaceuticalsType 2 diabetes mellitusEli LillyRisk of MIHeart failure hospitalizationRisk of HHFCardio-protective effectsCox regression modelAdvisory PanelCV deathCV diseaseFailure hospitalizationPlacebo groupDiabetes mellitusDohme Corp.Novo Nordisk A/STime-varying covariatesMerck Sharp19-LB: Consistent Cardiovascular (CV) Benefits from Empagliflozin across the Spectrum of CV Risk Factor Control: Post Hoc Analysis from EMPA-REG OUTCOME
INZUCCHI S, KHUNTI K, FITCHETT D, WANNER C, MATTHEUS M, GEORGE J, PERNILLE OFSTAD A, ZINMAN B. 19-LB: Consistent Cardiovascular (CV) Benefits from Empagliflozin across the Spectrum of CV Risk Factor Control: Post Hoc Analysis from EMPA-REG OUTCOME. Diabetes 2019, 68 DOI: 10.2337/db19-19-lb.Peer-Reviewed Original ResearchRisk factor goalsCV deathDohme Corp.Boehringer Ingelheim PharmaceuticalsNovo Nordisk A/SJanssen PharmaceuticalsMerck SharpTakeda Pharmaceutical Company LimitedHazard ratioRisk factorsNovartis AGEli LillyACE inhibitor/ARB useCV risk factor controlConsistent cardiovascular benefitEMPA-REG OUTCOMECV risk factorsRisk factor controlPfizer Inc.Sanofi-AventisNon-smoking statusAdvisory PanelPost Hoc AnalysisCV risk increasesARB use
2018
Empagliflozin (EMPA) Reduces Mortality and Hospitalization for Heart Failure (HHF) Irrespective of Cardiovascular (CV) Risk Score at Baseline
FITCHETT D, SCIRICA B, INZUCCHI S, CANNON C, MCGUIRE D, JOHANSEN O, SAMBEVSKI S, HEHNKE U, GEORGE J, ZINMAN B. Empagliflozin (EMPA) Reduces Mortality and Hospitalization for Heart Failure (HHF) Irrespective of Cardiovascular (CV) Risk Score at Baseline. Diabetes 2018, 67 DOI: 10.2337/db18-1123-p.Peer-Reviewed Original ResearchEMPA-REG OUTCOME trialBoehringer Ingelheim PharmaceuticalsBaseline CV riskCV deathProportion of patientsCause deathEisai Inc.CV riskOutcome trialsRisk scoreJanssen PharmaceuticalsGlaxoSmithKline plcBristol-Myers Squibb CompanyNovo Nordisk A/SLexicon PharmaceuticalsEli LillyBenefits of empagliflozinBoehringer Ingelheim GmbHResidual CV riskEffect of empagliflozinTIMI risk scorePfizer Inc.Sanofi-AventisCardiovascular risk scoreAmgen Inc.Composite Cardiovascular Risk Factor Target Achievement and Its Indicators in U.S. Adults with Diabetes—The Diabetes Collaborative Registry
WONG N, SONG Y, ARNOLD S, SPERLING L, CANNON C, INZUCCHI S, KOSIBOROD M. Composite Cardiovascular Risk Factor Target Achievement and Its Indicators in U.S. Adults with Diabetes—The Diabetes Collaborative Registry. Diabetes 2018, 67 DOI: 10.2337/db18-1487-p.Peer-Reviewed Original ResearchDiabetes Collaborative RegistryDiabetes mellitusBoehringer Ingelheim PharmaceuticalsJanssen PharmaceuticalsBristol-Myers Squibb CompanyCollaborative RegistryGlaxoSmithKline plcHigh-intensity statin usePfizer IncU.S. adultsBoehringer Ingelheim GmbHLow ASCVD riskRisk factor targetsAmgen Inc.Multiple logistic regressionAmgen IncASCVD preventionEisai Inc.ASCVD riskStatin useBlood pressureDM medicationsMultifactorial interventionMale sexNovo Nordisk A/S